pan-HER inhibitors
Aslan, ACT to Study Exceptional Responders to Pan-HER Inhibitor
The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.
The Asian cancer biotech firm will use ACT's genomic tools to research why some patients responded unusually well to its pan-HER inhibitor.